Best Peptides for Bodybuilding: What the Community Actually Stacks (2026)

The peptides most used for bodybuilding are the growth-hormone secretagogues: the CJC-1295 + ipamorelin "GH base" leads, followed by oral MK-677 and IGF-1 LR3, with BPC-157 + TB-500 logged for recovery. But "most stacked" is not the same as "most effective," none of these is FDA-approved for muscle, and all of them are banned in tested sport. This page answers the real question two ways at once: what the ProtocolPlus community actually stacks by phase, and what the evidence honestly says about each option.

Most "best peptides for bodybuilding" lists rank compounds by an author's opinion and quietly skip the parts that matter most: the full stacks, the cut-versus-bulk logic, the cycle ratios, and the anti-doping reality. We do it differently. The headline ranking below comes from first-party usage data, what ~2,600 ProtocolPlus users pursuing bodybuilding goals actually log, and we keep the editorial "why" (efficacy, suppression, legality, WADA status) clearly separate as context, never as the ranking. For the deep science on any single molecule we link up to its dedicated guide, so this page stays a clean decision hub that ranks and curates rather than re-explaining chemistry.

Key Takeaways

• What the community stacks (not an efficacy ranking): across ~2,600 ProtocolPlus users pursuing bodybuilding goals, the most-logged options are the CJC-1295 + ipamorelin GH base (34%), MK-677 (22%), and IGF-1 LR3 (14%), then BPC-157 + TB-500 for recovery (10%) and the cut-phase AOD-9604 (9%) (ProtocolPlus app data).
• Most stacked ≠ most effective. Usage reflects community word-of-mouth, availability, and hype as much as evidence. Read the ranking as a popularity signal, then weigh it against the honest-efficacy section below.
• None is FDA-approved for bodybuilding, and the human muscle-building data is thin. GH secretagogues raise your own GH and IGF-1; they are far less anabolic than steroids and should be expected to support recovery and body composition, not produce steroid-like mass.
• Stacks are phase-structured: a bulk runs the GH base + MK-677 (+ IGF-1 LR3 for advanced users); a cut keeps the GH base, drops MK-677, and adds a GH fragment (AOD-9604) or off-label tesamorelin plus BPC-157/TB-500 for joints; contest prep leans on recovery and joint resilience.
• Cycles, as logged: community-reported cycles run roughly 8 to 16 weeks, commonly 3-on / 1-off to limit desensitization. These are community conventions, not validated protocols.
• Anti-doping is the hard wall: every compound here is WADA-prohibited at all times (CJC-1295, ipamorelin, MK-677, hexarelin, IGF-1 LR3, MGF under S2; follistatin-related under S4.5; BPC-157 under S0). Natural federations test for them too. Filter the selector to "WADA-tested" and the compliant list is empty.

What peptides does the ProtocolPlus bodybuilding community stack?

Across ~2,600 ProtocolPlus users pursuing bodybuilding goals, the most-logged option is the CJC-1295 + ipamorelin GH base (34%), followed by oral MK-677 (22%) and IGF-1 LR3 (14%), then the BPC-157 + TB-500 recovery pairing (10%) and the cut-phase GH fragment AOD-9604 (9%) (ProtocolPlus app data, 2026). This is a usage ranking from our own app data, not a clinical verdict on what builds the most muscle.

The pattern is intuitive once you see it. The GH base dominates because it is the entry point: a GHRH analog paired with a selective secretagogue that raises the body's own pulsatile growth hormone with little of the cortisol or prolactin spike that older GHRPs cause. MK-677 sits second because it does the same job orally, no needles, with an appetite bump that suits a bulk. IGF-1 LR3 pulls a meaningful advanced cohort chasing the anabolic step downstream of GH. Then the tail: the BPC-157 + TB-500 recovery pairing (10%), AOD-9604 in cuts (9%), follistatin-344 among a small high-risk experimental group (6%), and hexarelin for raw GH spikes (5%).

These shares come only from our community-usage dataset and describe behavior, not efficacy. A compound can be widely stacked and weakly evidenced at the same time, and bodybuilding peptides are full of that gap: the human muscle-gain data behind every option here is thin, yet the stacks are confidently passed around. Read this chart as "what people in the community log," then cross-check it against the honest-efficacy section and the anti-doping wall further down.

Citation capsule. Among ~2,600 ProtocolPlus users who logged a bodybuilding goal, the most-logged options were CJC-1295 + ipamorelin (34%, 884 users), MK-677 (22%, 572), IGF-1 LR3 (14%, 364), BPC-157 + TB-500 (10%, 260), and AOD-9604 (9%, 234). Median logged cycle was ~8 to 16 weeks, commonly 3-on / 1-off. This is first-party usage data reflecting what the community uses, not a clinical efficacy ranking. Source: ProtocolPlus app data (goals/bodybuilding.json), 2026.

What does the community stack by phase: bulk, cut, and contest prep?

Bodybuilding peptide use is phase-structured: a bulk runs the GH base plus MK-677 and, for advanced users, IGF-1 LR3; a cut keeps the GH base, drops the appetite-raising MK-677, and adds a GH fragment or off-label tesamorelin plus BPC-157/TB-500 for joints; contest prep leans hardest on recovery and joint resilience. This phasing, not any single compound, is what the deep-funnel reader actually came for, and almost no competitor lays it out.

The logic is the same across phases: raise the GH/IGF-1 axis as a base, then add or subtract around the goal. In a bulk, the priority is anabolic signal and recovery volume, so MK-677's appetite and IGF-1 bump are features, not bugs, and the highest-risk experimental cohort layers IGF-1 LR3 or even follistatin-344 on top. In a cut, the same appetite bump becomes a liability, so MK-677 usually comes out, the GH base stays to protect lean mass in a deficit, and fat-loss-oriented compounds (AOD-9604, off-label tesamorelin) and joint support (BPC-157 + TB-500) come in. In contest prep, the body is under maximal stress at minimal calories, so recovery and joint resilience dominate while raw mass-building takes a back seat.

[UNIQUE INSIGHT] The honest read most lists skip is that the GH base barely changes across phases; what changes is the layer around it. That is why the community treats CJC-1295 + ipamorelin as a constant and treats everything else as phase-specific tooling. It also means the "best peptide for bodybuilding" question is malformed: the right answer is a phase-appropriate stack, not a single molecule, and the matrix below maps exactly which compound plays which role in each phase.

The bulk stack (mass phase)

The bulk stack is built bottom-up on the GH base. CJC-1295 + ipamorelin is the foundation, logged for raised pulsatile GH and IGF-1 with minimal cortisol or prolactin disturbance. On top of that, MK-677 is the most common add-on because it does the GH-secretagogue job orally and raises appetite, which helps hit a surplus, alongside more water retention. The advanced layer is IGF-1 LR3, used by a smaller cohort to push the IGF axis directly, and a high-risk fringe experiments with follistatin-344. The realistic expectation is recovery and fullness support, not a steroid-like mass jump.

The cut stack (lean-out phase)

The cut stack subtracts the appetite driver and adds fat-loss tooling. MK-677 usually comes out because the appetite and water that helped a bulk now blur conditioning. The GH base stays in to help preserve lean mass during a caloric deficit, which is its most defensible use. For fat loss, the community logs the GH fragment AOD-9604 or off-label tesamorelin, and for joint resilience under low calories and high volume, BPC-157 + TB-500. Note the honesty problem: AOD-9604 failed its human fat-loss trial, so its cut-phase popularity outruns its evidence. Dedicated cut-phase fat loss lives on the best peptides for weight loss and AOD-9604 guide.

The contest-prep stack

Contest prep is the most stressful phase, and the stack reflects it: recovery and joint resilience dominate while raw mass-building is parked. The GH base stays for lean-mass preservation, BPC-157 + TB-500 become the priority layer for soft-tissue and joint support under heavy training at minimal calories, and most other add-ons are dropped to keep conditioning clean. The hard caveat is that contest prep usually means a tested or natural federation, and every compound here is prohibited, so this phase is exactly where the anti-doping wall matters most.

Citation capsule. In community practice, bodybuilding peptide stacks are phase-structured around a constant GH base (CJC-1295 + ipamorelin): a bulk adds MK-677 (and advanced users IGF-1 LR3), a cut drops MK-677 and adds a GH fragment (AOD-9604) or off-label tesamorelin plus BPC-157 + TB-500 for joints, and contest prep emphasizes the BPC-157 + TB-500 recovery layer. These are community conventions, not validated protocols, and all compounds are WADA-prohibited. Source: ProtocolPlus app data, 2026; compound roles from community usage.

The community's most-logged stacks (by usage)

The community's three most-logged options are the CJC-1295 + ipamorelin GH base, oral MK-677, and IGF-1 LR3, the GH-and-IGF-axis core that anchors most bodybuilding stacks. Each card below pairs the usage share with the honest reason people log it and the caveat that comes with it.

These three account for roughly 70% of bodybuilding usage in our cohort. The split tracks a simple logic: build the GH/IGF axis first, then layer. The GH base is the universal entry point, MK-677 is the needle-free way to extend it, and IGF-1 LR3 is the advanced step downstream. The recovery pairing and cut tools fill the tail.

The long tail (ranks 4-7): the remaining ~30% of usage spreads across the BPC-157 + TB-500 recovery pairing (10%), the cut-phase AOD-9604 (9%), follistatin-344 (6%), and hexarelin (5%). BPC-157 + TB-500 is the recovery layer; AOD-9604 is the cut fat-loss tool with no human efficacy; follistatin-344 is the highest-risk myostatin experiment with animal data only; hexarelin is the strongest GH spiker but desensitizes fast. Each gets a mini-section below.

How do bodybuilding peptides actually work to build muscle?

Almost all the muscle-oriented peptides here work through one axis: they raise the body's own growth hormone (GH) and the downstream IGF-1 that mediates much of GH's anabolic effect, rather than acting like anabolic steroids that directly drive muscle-protein synthesis through the androgen receptor. That single fact explains both the ranking and the honest ceiling on what these compounds can do.

The mechanism splits into a few buckets. GHRH analogs (CJC-1295, tesamorelin, sermorelin) mimic the hypothalamic hormone that tells the pituitary to release GH. Ghrelin-mimetic secretagogues (ipamorelin, MK-677, hexarelin, the GHRP-2/GHRP-6 family) hit a second receptor to amplify and add to that GH pulse, which is why a GHRH plus a secretagogue (CJC-1295 + ipamorelin) is the classic base, two levers on the same pump. Direct IGF-axis agents (IGF-1 LR3, MGF) skip the GH step and signal anabolism directly. Myostatin inhibitors (follistatin-344) work on a different brake entirely, removing a natural limiter on muscle growth, which is why their animal data looks dramatic and their human risk profile looks frightening.

The two recovery compounds work on yet another premise. BPC-157 and TB-500 are not anabolic; they are logged for soft-tissue, tendon, and angiogenesis support so an athlete can train harder and recover faster, with tendon evidence that is preclinical only. The receptor-by-receptor science for any single compound lives on its hub; for the foundations of how injectable peptides act in the body, see how peptides work, and for GHRP-2/GHRP-6 specifically, that family is covered alongside the secretagogues here and in the broader GH-secretagogue literature (dedicated hub still to come, see debt note).

Citation capsule. Most bodybuilding peptides are growth-hormone secretagogues: GHRH analogs (CJC-1295, tesamorelin) and ghrelin-mimetics (ipamorelin, MK-677, hexarelin) raise endogenous GH and downstream IGF-1, while IGF-1 LR3 and MGF act on the IGF axis directly and follistatin-344 inhibits the myostatin brake. Unlike anabolic steroids, they do not directly activate the androgen receptor, so their anabolic ceiling is lower. Source: peer-reviewed endocrinology and GH-secretagogue literature, PubMed.

How effective are these peptides really, versus the bro-science?

Honestly: GH-secretagogue peptides raise GH and IGF-1 and can support recovery, sleep, and body composition, but the controlled human evidence that they add meaningful lean muscle in healthy, already-trained adults is thin, and the transformation claims passed around forums far outrun the data. This is the gap between what trials show and what marketing implies.

A few grounding facts. The clearest human GH-axis data come from older or clinically deficient populations, not lean trained lifters, and even the strongest secretagogue here, the FDA-approved GHRH analog tesamorelin, is approved for reducing visceral fat in HIV-associated lipodystrophy (FDA, Egrifta prescribing information, retrieved 2026-06-19), not for building muscle in athletes. MK-677 reliably raises GH and IGF-1 and lean body mass in studies, but a chunk of that early lean-mass change is water and the muscle-strength benefit in healthy young adults is far less established (Nass et al., Annals of Internal Medicine, 2008, retrieved 2026-06-19). And the two most-hyped "muscle" peptides, AOD-9604 and follistatin-344, have no human muscle-building efficacy at all.

[UNIQUE INSIGHT] The contrarian read the community resists is that the GH axis is a recovery-and-composition lever, not a mass lever. Steroids build muscle; GH peptides mostly help you recover to train and tighten body composition. Read against that frame, the ranking makes sense, the GH base wins because it is the safest, cleanest way to nudge that lever, and the high-anabolic-signal fringe (IGF-1 LR3, follistatin-344) sits low precisely because the risk-to-evidence ratio is awful. For grounded expectations and how to read transformation claims, see peptides before and after.

Citation capsule. GH-secretagogue peptides reliably raise GH and IGF-1, and MK-677 increases lean body mass in studies, but a portion is water and strength gains in healthy trained adults are not well established (Nass et al., Annals of Internal Medicine, 2008). The strongest, tesamorelin, is FDA-approved only for HIV-lipodystrophy visceral fat, not muscle building. AOD-9604 and follistatin-344 have no human muscle-gain efficacy. Source: Annals of Internal Medicine 2008; FDA Egrifta label.

Peptides vs steroids vs SARMs: which builds muscle, and at what risk?

On raw anabolic potency the ladder runs anabolic steroids first, SARMs second, GH-secretagogue peptides a distant third, but the risk, suppression, and legality picture inverts that order: peptides cause the least HPTA suppression, while steroids and SARMs deliver the mass and the hormonal cost. This three-way trade-off is the comparison every serious lifter wants and few "best peptides" lists will state plainly.

Here is the honest breakdown. Anabolic-androgenic steroids directly activate the androgen receptor, drive muscle-protein synthesis hard, and have decades of (mostly observational) human data, but they strongly suppress endogenous testosterone, require post-cycle therapy, and carry cardiovascular, hepatic, and endocrine risk. SARMs aim for tissue-selective androgen signaling with less of the cosmetic side-effect profile, but real-world products are unregulated, several do suppress testosterone, and some carry liver and lipid concerns. GH-secretagogue peptides work on a different axis entirely, so they do not directly suppress the HPTA and generally need no PCT on their own, but their anabolic ceiling is much lower and their muscle-gain evidence is thin. Crucially, all three are WADA-prohibited.

The detail that catches lifters out is the stacking interaction: when peptides are run alongside steroids or SARMs, the suppression and PCT burden comes from the steroid or SARM, not the peptide, but the peptide's GH/IGF-1 elevation can compound metabolic strain (insulin sensitivity, water, cardiac load). So "peptides are safer" is true only when peptides are used alone; in a combined cycle, the riskiest component sets the risk floor. For the dedicated head-to-head on hormonal-anabolic versus peptide approaches, see peptides vs steroids, and the SARMs comparison is covered there as well (a dedicated peptides-vs-SARMs hub is still to come, see debt note).

How long is a bodybuilding peptide cycle, and what are the on-off ratios?

Community-reported cycles for the GH-secretagogue base run roughly 8 to 16 weeks, most often on a 3-weeks-on, 1-week-off pattern, with some users running GH secretagogues continuously for months; the off periods exist mainly to limit receptor desensitization, which is worst with the stronger GHRPs like hexarelin. These are logged community conventions, framed as data, not validated dosing protocols or recommendations.

A few patterns recur in the logs. The cleaner secretagogues (ipamorelin, CJC-1295) desensitize less, so people run them longer and worry about cycling less; hexarelin desensitizes fast and is the one most often pulsed on and off. MK-677 is frequently run in longer blocks because its half-life supports once-daily oral dosing, with breaks taken more for appetite and water than for receptor reasons. IGF-1 LR3, when used at all, is typically run in shorter advanced blocks because of its potency and metabolic risk. The honest framing is that none of these has an established bodybuilding cycle in trials, so every figure here describes what the community does, not what is proven safe or optimal.

[PERSONAL EXPERIENCE] In our reading of these logs, the recurring mistake is treating "on-off ratio" as if it were a validated science. It is not. The ratios are folk conventions to manage desensitization, and we deliberately publish no milligram doses here: that belongs on each compound's hub, framed as "studied in trials," not as a protocol. The cycle table below summarizes the community-reported ranges so they sit in one place, clearly labeled as community convention.

Citation capsule. Community-reported bodybuilding peptide cycles run roughly 8 to 16 weeks, commonly 3-weeks-on / 1-week-off, with off periods used to limit GH-receptor desensitization that is worst with stronger GHRPs like hexarelin. These are community conventions logged in the app, not validated dosing protocols; no peptide here has an established bodybuilding cycle in clinical trials. Source: ProtocolPlus app data, 2026.

Do bodybuilding peptides suppress testosterone or need PCT?

On their own, GH-secretagogue peptides act on the growth-hormone axis, not the hypothalamic-pituitary-gonadal axis, so they generally do not suppress endogenous testosterone and do not require post-cycle therapy; the suppression-and-PCT question only becomes real when peptides are stacked with anabolic steroids or SARMs, which do suppress. Getting this distinction right prevents both needless PCT and dangerous complacency.

The mechanism is the reason. Testosterone suppression happens when exogenous androgens (steroids, some SARMs) signal the brain to shut down its own production via the HPTA, which is why those cycles need recovery support afterward. GH secretagogues do not touch that loop directly; they nudge GH and IGF-1, a separate axis. So a peptide-only GH-base cycle typically needs no PCT. The trap is the combined cycle: when someone runs peptides alongside a steroid or SARM, the suppression is real but it comes from the androgenic compound, and the peptide can add metabolic strain on top (insulin sensitivity, water, cardiac load). The riskiest component sets the risk floor, and that conversation belongs with a clinician, not a forum.

Each candidate, briefly (with where to go deeper)

Here is each of the main compounds in two-to-four sentences, enough to place it in a stack, with a link up to its full guide for the science. This page owns the "which stack, which phase, and why" decision; the mechanism, dosing, and side-effect depth live on each compound's hub.

CJC-1295 + Ipamorelin (the GH base)

The community's foundation stack: a GHRH analog (CJC-1295) paired with a selective ghrelin-mimetic (ipamorelin) to raise pulsatile GH and IGF-1 with minimal cortisol or prolactin. It is research-grade, has thin human muscle-gain evidence, and is WADA-prohibited. Full mechanism and dosing: CJC-1295 guide and ipamorelin guide.

MK-677 (Ibutamoren)

An oral ghrelin-mimetic GH secretagogue, the default bulk add-on because it raises GH/IGF-1 and appetite without needles. It increases lean body mass in studies (partly water), can dent insulin sensitivity, was never FDA-approved, and is WADA-prohibited. Full guide: MK-677 guide.

IGF-1 LR3

A long-acting IGF-1 analog used by an advanced cohort to push the IGF axis directly during a bulk. It carries hypoglycemia and theoretical proliferative risk, has no human bodybuilding efficacy data, and is WADA-prohibited. Full guide: IGF-1 LR3 guide.

MGF (mechano growth factor)

A splice variant of IGF-1 studied for local muscle-repair signaling after mechanical load, used by a small advanced cohort around training. Its human muscle-building evidence is minimal and it is research-grade and WADA-prohibited. Full guide: MGF guide.

BPC-157 + TB-500 (the recovery pairing)

The recovery layer rather than a muscle builder: BPC-157 and TB-500 are logged for soft-tissue, tendon, and angiogenesis support so athletes can train and recover harder. Tendon evidence is preclinical only, both are research-grade, and both are WADA-prohibited. Deep recovery and tendon use lives on best peptides for recovery; hubs: BPC-157 guide, TB-500 guide.

AOD-9604 (the cut fragment)

A GH fragment (176-191) logged in cuts by users wanting fat loss without MK-677's appetite and water. Its Phase 2b fat-loss trial failed to beat placebo, so its cut-phase popularity outruns its evidence. Cut-phase fat loss belongs on best peptides for weight loss; hub: AOD-9604 guide.

Follistatin-344

A myostatin-inhibiting protein with dramatic animal hypertrophy data and a small high-risk experimental following. There is no human muscle-building efficacy data, the systemic and proliferative risk is serious and unknown, and it is tied to gene-doping concerns and WADA-prohibited. Full guide: follistatin-344 guide.

Hexarelin

The most potent GHRP for acute GH release, used over ipamorelin by a cohort chasing raw GH spikes. It desensitizes quickly and can raise prolactin and cortisol with continuous use, so it needs on-off cycling; research-grade and WADA-prohibited. Full guide: hexarelin guide.

Tesamorelin and Sermorelin (the GHRH analogs)

Tesamorelin is the one FDA-approved GHRH analog here, approved for HIV-associated lipodystrophy (visceral fat), used off-label in cuts; sermorelin is a shorter-acting GHRH analog sometimes used as a gentler base. Neither is approved for bodybuilding, both are off-label or research-grade for this use, and both are WADA-prohibited. Hubs: tesamorelin guide, sermorelin guide.

GHRP-2 and GHRP-6 (the older secretagogues)

The earlier GHRP family that ipamorelin largely replaced, still used by some for stronger GH release and (with GHRP-6) appetite. They raise prolactin and cortisol more than ipamorelin, which is why the modern base swapped them out. No dedicated hub yet (see debt note); for the GH-secretagogue comparison and hormonal-versus-peptide framing, see peptides vs steroids.

What does WADA status mean for competitive and natural-federation athletes?

For any athlete in a drug-tested sport, including tested natural bodybuilding federations, every compound on this page is prohibited: GH secretagogues (CJC-1295, ipamorelin, MK-677, hexarelin, GHRP-2/6) and growth factors (IGF-1 LR3, MGF) sit under S2, follistatin-related agents under S4.5, and BPC-157 under S0, all banned at all times, in and out of competition. There is no compliant muscle-building peptide here, which is the single biggest gap in every "best peptides for bodybuilding" article that name-drops WADA without explaining it.

The practical meaning is stricter than most assume, and the in-competition versus out-of-competition distinction is where lifters get caught. Substances banned only "in competition" can sometimes be used in the off-season, but the GH secretagogues, growth factors, and BPC-157 here are all prohibited at all times, so an out-of-competition injection during a bulk can still produce an adverse finding months later. S0 (non-approved substances) exists precisely to catch compounds with no approved human therapeutic use, which is the bucket BPC-157 falls into, so "it isn't specifically named" is not a defense, the category is the rule. A Therapeutic Use Exemption is theoretically possible but realistically very hard for a non-approved research chemical with no validated human protocol.

[PERSONAL EXPERIENCE] In our reading of athlete cases, the recurring mistake is assuming "natural" federations only test for steroids. They test for peptides too, and a GH-secretagogue stack run in the off-season is exactly the kind of out-of-competition use that ends a natural career. The WADA Prohibited List is updated annually and categories can shift, so a tested athlete should verify the current list directly (WADA Prohibited List, 2026). For tested and natural-federation competitors, the honest shortlist of compliant muscle-building peptides on this page is empty.

Citation capsule. Under the 2026 WADA Prohibited List, GH secretagogues (CJC-1295, ipamorelin, MK-677, hexarelin) and growth factors (IGF-1 LR3, MGF) are prohibited under S2, follistatin-related agents under S4.5, and BPC-157 under S0, all banned at all times for tested athletes, including tested natural bodybuilding federations (WADA Prohibited List, 2026). There is no anti-doping-compliant muscle-building peptide. The list updates annually, so athletes must verify the current version. Source: World Anti-Doping Agency, 2026.

What the community stacks is not what is proven best

Treat the usage ranking as a popularity signal shaped by community word-of-mouth, availability, and hype, not as evidence of what builds the most muscle or is safest. The clearest proof is on this very page: two of the most-discussed "muscle" peptides, AOD-9604 (failed its fat-loss trial) and follistatin-344 (animal data only, serious unknown risk), still pull real usage despite the worst evidence-to-risk ratios in the set.

Three honest framings sit on top of every number here. First, no compound on this page is FDA-approved for bodybuilding, and the human muscle-gain evidence is thin even for the GH base; the strongest, tesamorelin, is approved only for HIV-lipodystrophy. Second, anti-doping status is a hard wall, not a footnote: every option is WADA-prohibited at all times, and tested natural federations test for them, so a competitor's real compliant shortlist is zero. Third, research-grade vials carry quality risk, unknown potency, purity, and sterility, that no usage statistic captures, and the suppression math changes the moment peptides are stacked with steroids or SARMs. Before sourcing anything, see how to vet peptide quality and are peptides legal.

Our take: The most useful way to read this page is as two layers. The usage chart and phase matrix tell you what real lifters are doing; the efficacy and WADA sections tell you what the data and the rules support. When those layers agree, as they do for the GH base being the cleanest entry, that is the signal worth trusting. When they diverge, as with follistatin-344 and AOD-9604, trust the evidence, not the crowd.

Where this page stops, and where to go next

This page is scoped to the competitive and advanced bodybuilding intent: full stacks, bulk/cut/contest-prep phasing, cycle and on-off ratios, the peptides-vs-steroids-vs-SARMs trade-off, and the WADA and natural-federation reality, and it deliberately hands the adjacent questions to sibling guides so nothing gets half-answered. Matching the page to your actual question matters more than the compound you pick.

A few clean boundaries keep this useful. Single-compound mechanism, lean-mass for beginners, and the "safest single peptide" question live on best peptides for muscle growth. Cut-phase fat loss belongs on best peptides for weight loss and the AOD-9604 guide. Deep recovery, tendon, and joint use of BPC-157 and TB-500 lives on best peptides for recovery. The hormonal-versus-peptide head-to-head, including SARMs, is on peptides vs steroids. Keep the page that matches your goal; cross-link, do not blend.

Who should be cautious, and who should not use these

Bodybuilding peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight. None is FDA-approved for muscle building, none has a validated human dosing protocol for this use, and the high-anabolic-signal compounds add serious unknown risk on top.

A few hard lines worth stating. There is no FDA-approved peptide for bodybuilding, so every compound here is used off-label or as a research chemical with no validated dose, duration, or safety profile in athletes. IGF-1 LR3 and follistatin-344 deserve particular caution: systemic IGF-1 signaling carries hypoglycemia and theoretical proliferative risk, and follistatin-344 has serious unknown systemic risk with no human efficacy data. MK-677 can worsen insulin sensitivity and raise water and appetite, which matters for anyone with metabolic risk. Tested and natural-federation athletes should treat every compound here as prohibited and verify the current WADA list, since classifications update annually. And anyone stacking peptides with steroids or SARMs inherits the suppression and cardiovascular risk of those compounds. Anyone with a relevant medical history, including cancer or diabetes, should not self-direct these. None of this page is a substitute for that conversation with a qualified clinician.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for bodybuilding," the honest answer is that the question is malformed: the community uses phase-appropriate stacks, not one molecule. The most-logged foundation is the CJC-1295 + ipamorelin GH base, and it is the cleanest, lowest-risk entry, with MK-677 layered for a bulk, IGF-1 LR3 added by advanced users, AOD-9604 or tesamorelin in cuts, and BPC-157 + TB-500 carrying recovery, especially in contest prep. But the GH axis is a recovery-and-composition lever, not a mass lever, so set expectations against the evidence, not the forums.

Two hard truths sit under everything here. None of these is FDA-approved for muscle building and the human muscle-gain data is thin, and every compound is WADA-prohibited at all times, with tested natural federations testing for them too, so a competitor's compliant shortlist is empty. The selector at the top narrows the field to your phase, route, and competition status, but the final call belongs with a clinician who knows your health history. From here, the natural next reads are the peptides vs steroids head-to-head, the best peptides for muscle growth guide, and how to vet peptide quality.

Sources

• Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine, 2008. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/19017583/
• U.S. Food & Drug Administration. "Egrifta (tesamorelin) for injection — Prescribing Information" (approved for HIV-associated lipodystrophy / visceral adipose tissue reduction). 2014. Retrieved 2026-06-19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022505s007lbl.pdf
• Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues (GHRH analogs and GHRPs)." Sexual Medicine Reviews / PubMed, 2018. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/28526632/
• Lee SJ, et al. "Regulation of muscle mass by myostatin and follistatin (preclinical hypertrophy data)." PNAS / PubMed, preclinical. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/15784737/
• Stanford SC, et al. (review). "AOD-9604 and obesity pharmacotherapy (Phase 2b did not beat placebo)." PMC3584306. Retrieved 2026-06-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/
• World Anti-Doping Agency. "The Prohibited List" (S0 non-approved substances; S2 peptide hormones, growth factors and mimetics; S4.5 myostatin-related agents; prohibited at all times). 2026. Retrieved 2026-06-19. https://www.wada-ama.org/en/prohibited-list
• ProtocolPlus. "Community goal-usage data: bodybuilding" (goals/bodybuilding.json). First-party app data, 2026. n ≈ 2,600 users pursuing bodybuilding goals; median cycle ~8 to 16 weeks, commonly 3-on / 1-off. Usage signal, not a clinical efficacy ranking.